title: The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.
abstract: The current study assesses the antihypertensive efficacy and safety of the investigational angiotensin receptor blocker (ARB), azilsartan medoxomil (AZL-M), compared with placebo and the ARB olmesartan medoxomil (OLM-M). This randomized, double-blind, placebo-controlled, multicenter study assessed change from baseline in mean 24-hour ambulatory systolic blood pressure (SBP) following 6 weeks of treatment. Patients with primary hypertension (n=1275) and baseline 24-hour mean ambulatory systolic pressure ≥ 130 mm Hg and ≤ 170 mm Hg were studied; 142 received placebo and the remainder received 20 mg, 40 mg, or 80 mg AZL-M or 40 mg OLM-M. Mean age of participants was 58 ± 11 years, baseline mean 24-hour SBP was 146 mm Hg. Dose-dependent reductions in 24-hour mean SBP at study end occurred in all AZL-M groups. Reduction in 24-hour mean SBP was greater with AZL-M 80 mg than OLM-M 40 mg by 2.1 mm Hg (95% confidence interval, -4.0 to -0.1; P=.038), while AZL-M 40 mg was noninferior to OLM-M 40 mg. The side effect profiles of both ARBs were similar to placebo. AZL-M is well tolerated and more efficacious at its maximal dose than the highest dose of OLM-M.
authors.affiliation: Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA. gbakris@gmail.com
authors.forename: George L
authors.initials: GL
authors.lastname: Bakris
authors.forename: Domenic
authors.initials: D
authors.lastname: Sica
authors.forename: Michael
authors.initials: M
authors.lastname: Weber
authors.forename: William B
authors.initials: WB
authors.lastname: White
authors.forename: Andrew
authors.initials: A
authors.lastname: Roberts
authors.forename: Alfonso
authors.initials: A
authors.lastname: Perez
authors.forename: Charlie
authors.initials: C
authors.lastname: Cao
authors.forename: Stuart
authors.initials: S
authors.lastname: Kupfer
mesh_terms: D000368:Aged; D057911:Angiotensin Receptor Antagonists / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001118:Argentina; D001562:Benzimidazoles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology*; D001795:Blood Pressure Determination; D018660:Blood Pressure Monitoring, Ambulatory; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000208:ethnology / Q000503:physiopathology; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008800:Mexico; D008875:Middle Aged; D010069:Oxadiazoles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D010568:Peru; D044469:Racial Groups / Q000208:ethnology; D013777:Tetrazoles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States
chemical_list: D057911:Angiotensin Receptor Antagonists; D001562:Benzimidazoles; D007093:Imidazoles; D010069:Oxadiazoles; D013777:Tetrazoles; C437965:olmesartan; C557413:azilsartan medoxomil